2024
Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Bewersdorf J, Derkach A, Zeidan A, Stein E, Mauro M, Podoltsev N, Rampal R. Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 2024, 144: 6659-6659. DOI: 10.1182/blood-2024-194918.Peer-Reviewed Original ResearchDose-limiting toxicityCancer Institute Common Terminology Criteria for Adverse EventsTreatment-related adverse eventsAdverse eventsDose levelsCombination therapySpleen volumeInhibitor abemaciclibGrade 3Patients discontinued treatment due to adverse eventsNational Cancer Institute Common Terminology Criteria for Adverse EventsPhase I dose-escalation trialTreatment due to adverse eventsCommon Terminology Criteria for Adverse EventsDisease progressionRecommended phase II doseMulticenter Phase IPlanned dose levelsGrade 3 thrombocytopeniaMedian overall survivalPhase II doseBone marrow blastsBone marrow fibrosisClinically significant bleedingData cut-off
2023
A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
Bewersdorf J, Derkach A, Masarova L, Pemmaraju N, Stein E, Mauro M, Rampal R, Bose P. A Phase I Study of Ruxolitinib in Combination with Abemaciclib for Patients with Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis. Blood 2023, 142: 6440. DOI: 10.1182/blood-2023-174322.Peer-Reviewed Original ResearchDuration of responseMaximum tolerated doseDose of ruxolitinibCDK4/6 inhibitorsStable doseTolerated doseHormone receptor-positive metastatic breast cancerRisk of progression to acute myeloid leukemiaSymptom scoresPhase I dose-escalation trialProgression to acute myeloid leukemiaTreatment of hormone receptor-positive metastatic breast cancerAbsolute neutrophil count <Cancer CenterCombination of CDK4/6 inhibitorsUS FDAMemorial Sloan Kettering Cancer CenterGrade 1 diarrheaMedian overall survivalPre-study doseDose-limiting toxicityMD Anderson Cancer CenterBone marrow fibrosisNeutrophil count <Platelet count <
2019
Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis
Bewersdorf JP, Jaszczur SM, Afifi S, Zhao JC, Zeidan AM. Beyond Ruxolitinib: Fedratinib and Other Emergent Treatment Options for Myelofibrosis. Cancer Management And Research 2019, 11: 10777-10790. PMID: 31920387, PMCID: PMC6935287, DOI: 10.2147/cmar.s212559.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTreatment optionsFavorable risk/benefit ratioRisk/benefit ratioEmergent treatment optionsHigh-risk patientsPhase II trialMain side effectsFuture treatment optionsBone marrow fibrosisGastrointestinal symptomsII trialLiver transaminasesAdverse eventsSymptom burdenOngoing trialsJAK1/2 inhibitorMF patientsMarrow fibrosisClinical trialsSecondary myelofibrosisBox warningSelective JAK2 inhibitorExtramedullary hematopoiesisSecond drugThiamine levels